NasdaqGS - Delayed Quote • USD
REGENXBIO Inc. (RGNX)
At close: June 11 at 4:00 PM EDT
After hours: June 11 at 4:04 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
86,726.00
90,242.00
112,724.00
470,347.00
154,567.00
Cost of Revenue
37,384.00
37,213.00
54,545.00
51,833.00
35,714.00
Gross Profit
49,342.00
53,029.00
58,179.00
418,514.00
118,853.00
Operating Expense
313,075.00
321,157.00
321,055.00
258,534.00
238,086.00
Operating Income
-263,733.00
-268,128.00
-262,876.00
159,980.00
-119,233.00
Net Non Operating Interest Income Expense
-6,088.00
-6,837.00
-22,912.00
-25,558.00
3,500.00
Other Income Expense
9,521.00
11,319.00
5,383.00
6,825.00
9,723.00
Pretax Income
-260,300.00
-263,646.00
-280,405.00
141,247.00
-106,010.00
Tax Provision
--
-152.00
-84.00
13,407.00
5,240.00
Net Income Common Stockholders
-260,148.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Diluted NI Available to Com Stockholders
-260,148.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Basic EPS
-5.87
-6.02
-6.50
3.01
-2.98
Diluted EPS
-5.87
-6.02
-6.50
2.91
-2.98
Basic Average Shares
44,304.50
43,734.00
43,152.00
42,438.00
37,281.00
Diluted Average Shares
44,304.50
43,734.00
43,152.00
43,913.00
37,281.00
Total Operating Income as Reported
-265,834.00
-268,128.00
-262,876.00
159,980.00
-119,233.00
Total Expenses
350,459.00
358,370.00
375,600.00
310,367.00
273,800.00
Net Income from Continuing & Discontinued Operation
-260,148.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Normalized Income
-269,669.00
-274,806.47
-285,702.39
121,662.82
-118,347.79
Interest Income
-8.00
25.00
342.00
719.00
4,271.00
Interest Expense
6,080.00
6,862.00
23,254.00
26,277.00
771.00
Net Interest Income
-6,088.00
-6,837.00
-22,912.00
-25,558.00
3,500.00
EBIT
-254,220.00
-256,784.00
-257,151.00
167,524.00
-105,239.00
EBITDA
-236,898.00
-239,464.00
-244,242.00
177,088.00
-96,832.00
Reconciled Cost of Revenue
37,384.00
37,213.00
54,545.00
51,833.00
35,714.00
Reconciled Depreciation
17,322.00
17,320.00
12,909.00
9,564.00
8,407.00
Net Income from Continuing Operation Net Minority Interest
-260,148.00
-263,494.00
-280,321.00
127,840.00
-111,250.00
Total Unusual Items Excluding Goodwill
9,521.00
11,319.00
5,383.00
6,825.00
9,723.00
Total Unusual Items
9,521.00
11,319.00
5,383.00
6,825.00
9,723.00
Normalized EBITDA
-246,419.00
-250,783.00
-249,625.00
170,263.00
-106,555.00
Tax Rate for Calcs
--
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
6.53
1.61
647.82
2,625.21
12/31/2020 - 9/17/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
QURE uniQure N.V.
5.23
-2.79%
FDMT 4D Molecular Therapeutics, Inc.
23.29
+3.19%
IRON Disc Medicine, Inc.
39.13
-1.49%
ADVM Adverum Biotechnologies, Inc.
7.31
-2.53%
VYGR Voyager Therapeutics, Inc.
8.67
-1.14%
RARE Ultragenyx Pharmaceutical Inc.
41.40
-1.36%
ALEC Alector, Inc.
4.4200
0.00%
DNLI Denali Therapeutics Inc.
21.60
+2.76%
PTCT PTC Therapeutics, Inc.
37.69
+0.21%
SABS SAB Biotherapeutics, Inc.
3.3900
+2.11%